– The VENITI VICI VENOUS STENT® offers enhanced value to physicians treating CVD patients
LONDON, Feb. 9, 2015 /PRNewswire/ — Based on its recent analysis of the peripheral vascular devices market, Frost & Sullivan recognises VENITI™, Inc. with the 2015 European Frost & Sullivan Award for New Product Innovation. VENITI’s focus on innovation and fostering close relations with customers has leant the brand considerable heft in the peripheral vascular devices market. The company stands out for consistently ensuring maximum return on investment by improving workflows and enhancing the quality of care for patients.
The stents currently used for cardio vascular diseases include re-purposed vascular stents that were originally designed and manufactured to be used in the arterial system. However, as the hemodynamics, physiology, and pathophysiology of the arterial system are different from the venous system, there is a need for a stent manufactured specifically for the venous system. VENITI addresses this need with its VICI VENOUS STENT, which is designed to combat the peculiar anatomy and pathology of the venous system.
"The VICI VENOUS STENT delivers critical advantages such as superior end-to-end crush resistance and excellent vein wall coverage, while providing necessary flexibility for the venous system," said Frost & Sullivan Research Analyst Parthasarathy Raghava. "Its uniform end-to-end strength and shape provides excellent blood inflow as well as outflow, minimizing post-operative complications. Furthermore, it can be easily deployed and is highly controlled to eliminate jumping, which is a risk with other systems."
VENITI is now developing second-generation stents and pursuing complementary technology and products to treat CVD. It has also commenced the VIRTUS trial, a prospective multicenter, 200-patient study to assess the safety and efficacy of the VICI VENOUS STENT in achieving patency of the target venous lesion.
Owing to these product advantages and a robust sales and marketing team, Frost & Sullivan expects VENITI’s revenue in the European chronic venous disease market to grow significantly in 2015. Additionally, VENITI has several distribution partnerships with multiple companies across the entire European region. It has ensured that its customers, which are primarily hospitals and clinics, have easy access to its product through local representation in each of its markets.
"The VENITI VICI VENOUS STENT possesses superior crush resistance and substantial vein coverage," avers Frost & Sullivan Research Analyst Sowmya Rajagopalan. "Its success has proved beyond doubt that the VICI VENOUS STENT is a superior solution for patients with symptomatic venous outflow obstruction."
Each year, Frost & Sullivan presents this award to the company that that has developed an innovative element in a product by leverage leading-edge technologies. The award recognises the value added features/benefits of the product and the increased ROI it offers customers, which in turn increases customer acquisition and overall market penetration potential.
Frost & Sullivan Best Practices awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
About VENITI™, Inc.
VENITI, Inc. is an early-stage commercialization company that is headquartered in St. Louis, MO and has technical operations in Fremont, CA. Founded in 2010, it is dedicated to advancing the treatment of venous disease through innovative technology and solutions. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI® VENOUS STENT System. In launching the Venous Stent System, VENITI partners with individuals and companies with leadership roles in the development and training for therapies to provide advancement of care in venous disease. Through this, and other innovative technology, VENITI will achieve results that set it apart in addressing the challenges specific to the venous system and venous disease The Venous Stent System is CE marked under the European Medical Devices Directive (93/42/EEC) and commercially available in Europe. CAUTION: Investigational device. Limited by United States law to investigational use. VENITI is a trademark of VENITI, Inc. VICI VENOUS STENT is a registered trademark of VENITI, Inc. ©2015 VENITI, Inc. All Rights Reserved. Produced in the U.S. For more information, please visit www.veniti.com.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Best Practices Group
Frost & Sullivan